Moderator Christoph Correll, MD, conducts a series of investigative interviews with a fellow healthcare professional, exploring each aspect of Major Depressive Disorder and PTSD from a new lens.

Major depressive disorder (MDD) affects approximately 280 million people globally and is one of the leading causes of ...

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

Study finds AI chatbot significantly improve symptoms for those suffering from major depressive disorder (MDD), generalized ...

An experiment involving women with major depressive disorder found improvements in their quality of life, emotion regulation strategies, and everyday depression symptoms following group music therapy.

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Smoking and depression - Gemma Taylor discusses the effects of smoking cessation treatment options for people with past or ...

After Axsome Therapeutics (AXSM) yesterday reported negative results from its Phase 3 major depressive disorder trial evaluating Sunosi as a ...

Discover the overlooked mental health condition of dysthymia through Baek Sehee's therapy memoir, sparking an important ...

Adults showed a significant reduction in their clinical-level mental health symptoms with unrestricted access to a generative ...

Axsome Therapeutics (AXSM) announced results of the PARADIGM Phase 3 proof-of-concept trial of solriamfetol in major depressive disorder, MDD, ...